Nogueira, E., Freitas, J., Loureiro, A., Nogueira, P., et al. (2017). Neutral PEGylated liposomal formulation for efficient folate-mediated delivery of MCL1 siRNA to activated macrophages. Colloids and Surfaces B: Biointerfaces, 155, 459 - 465.

Nogueira, E., Cruz, C. F., Loureiro, A., Nogueira, P., et al. (2016). Assessment of liposome disruption to quantify drug delivery in vitro. Biochimica et Biophysica Acta - Biomembranes, 1858(2), 163 - 167.

Nogueira, E., Mangialavori, I. C., Loureiro, A., Azoia, N. G., et al. (2015). Peptide Anchor for Folate-Targeted Liposomal Delivery. Biomacromolecules, 16(9), 2904 - 2910.

Rollett, A., Reiter, T., Nogueira, P., Cardinale, M., et al. (2012). Folic acid-functionalized human serum albumin nanocapsules for targeted drug delivery to chronically activated macrophages. International Journal of Pharmaceutics, 427(2), 460 - 466.

Costa, E., Rocha, S., Rocha-Pereira, P., Reis, F., et al. (2009). Effect of hemodialysis procedure in prohepcidin serum levels in regular hemodialysis patients. Clinical Nephrology, 71(2), 233 - 235.

Costa, E., Swinkels, D. W., Laarakkers, C. M., Rocha-Pereira, P., et al. (2009). Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients. Acta Haematologica, 122(4), 226 - 229.

Costa, E., Rocha, S., Rocha-Pereira, P., Castro, E., et al. (2008). Altered erythrocyte membrane protein composition in chronic kidney disease stage 5 patients under haemodialysis and recombinant human erythropoietin therapy. Blood Purification, 26(3), 267 - 273.

Costa, E., Rocha, S., Rocha-Pereira, P., Castro, E., et al. (2008). Changes in red blood cells membrane protein composition during hemodialysis procedure. Renal Failure, 30(10), 971 - 975.

Costa, E., Rocha, S., Rocha-Pereira, P., Castro, E., et al. (2008). Cross-talk between inflammation, coagulation/fibrinolysis and vascular access in hemodialysis patients. Journal of Vascular Access, 9(4), 248 - 253.

Costa, E., Rocha, S., Rocha-Pereira, P., Reis, F., et al. (2008). DMT1 (NRAMP2/DCT1) Genetic Variability and Resistance to Recombinant Human Erythropoietin Therapy in Chronic Kidney Disease Patients under Haemodialysis. Acta Haematologica, 120(1), 11 - 13.

Costa, E., Lima, M., Rocha, S., Rocha-Pereira, P., et al. (2008). IL-7 serum levels and lymphopenia in hemodialysis patients, non-responders to recombinant human erythropoietin therapy. Blood Cells, Molecules, and Diseases, 41(1), 134 - 135.

Costa, E., Lima, M., Alves, J. M., Rocha, S., et al. (2008). Inflammation, T-cell phenotype, and inflammatory cytokines in chronic kidney disease patients under hemodialysis and its relationship to resistance to recombinant human erythropoietin therapy. Journal of Clinical Immunology, 28(3), 268 - 275.

Costa, E., Rocha, S., Rocha-Pereira, P., Nascimento, H., et al. (2008). Neutrophil activation and resistance to recombinant human erythropoietin therapy in hemodialysis patients. American Journal of Nephrology, 28(6), 935 - 940.

Costa, E., Pereira, B. J. G., Rocha-Pereira, P., Rocha, S., et al. (2008). Role of prohepcidin, inflammatory markers and iron status in resistance to rhEPO therapy in hemodialysis patients. American Journal of Nephrology, 28(4), 677 - 683.